Rtw Investments Adds $14M in Definium Therapeutics, Inc. ($DFTX)
Rtw Investments has acquired 300,000 shares of Definium Therapeutics, valued at $11 million.
Key Points
- Rtw Investments has taken a new position in Definium Therapeutics, acquiring 300,000 shares worth $11 million.
- Shares of Definium Therapeutics traded near $36.67, with a market cap of $3.99 billion and a 52-week high of $39.16.
- Insiders, including the CEO, bought shares, and analysts maintain a 'buy' rating with targets up to $60.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Rtw Investments has taken a new position in Definium Therapeutics, Inc. (NasdaqGS: DFTX), acquiring 300,000 shares valued at approximately $11 million. This move, disclosed in a recent SEC filing, marks a new investment for the fund.
Rtw Investments vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
What Changed in Rtw Investments' Definium Therapeutics Position
Rtw Investments opened a new stake in Definium Therapeutics by purchasing 300,000 shares. This investment, valued at around $11 million, reflects the fund's interest in the biotechnology company as of the most recent reporting period.
Other Institutional Activity in Definium Therapeutics
Several other institutional investors have shown interest in Definium Therapeutics. BlackRock, Inc. opened a new position with 8,480,230 shares valued at $160.3 million. Driehaus Capital Management LLC reduced its holdings by 625,313 shares, leaving it with 5,911,889 shares worth about $111.7 million, a 9.6% decrease. Avoro Capital Advisors LLC also initiated a new position with 5,000,000 shares valued at $94.5 million. Janus Henderson Group PLC and Deep Track Capital, LP both opened new positions with 3,556,041 shares and 3,000,000 shares, respectively.
Definium Therapeutics, Inc. Stock Up 14.8%
On Tuesday, shares of Definium Therapeutics traded near $36.67. The company has a market capitalization of approximately $4 billion and a beta of 2.378, indicating higher volatility compared to the market. The stock's 52-week range is between $6.35 and $39.16, with a 50-day moving average of $22.61 and a 200-day moving average of $16.28. Definium's current ratio is strong at 4.692, and its quick ratio is 4.604, reflecting solid liquidity.
$DFTX stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at Definium Therapeutics, Inc.
On June 22, 2026, several insiders at Definium Therapeutics, including CEO Robert Barrow, purchased shares. Barrow acquired 375,000 shares, while other executives like Chief Medical Officer Daniel Karlin and Chief Legal Officer Mark Sullivan bought 100,000 and 62,500 shares, respectively. These transactions were not part of a pre-planned trading program.
Analysts Set New Price Targets
Analysts have shown strong support for Definium Therapeutics. On June 22, 2026, Leerink Partners and Oppenheimer both maintained their 'buy' ratings, with price targets of $52 and $60, respectively. Canaccord Genuity has also maintained a 'buy' rating, setting a target of $38 on June 16, 2026. The consensus among analysts is a 'strong buy', with an average target price of $39.87 across 15 opinions.
About Definium Therapeutics
Definium Therapeutics, Inc., headquartered in New York, is a biotechnology company focused on developing treatments for brain health disorders. Led by CEO Robert Barrow, the company is advancing its lead product candidates, DT120 and DT402, through various clinical trial phases. With 105 employees, Definium aims to address conditions like anxiety, depression, and autism spectrum disorder.
Bottom Line
Rtw Investments' new position in Definium Therapeutics reflects growing institutional interest in the company. While the 13F filing is backward-looking, it provides insight into investor sentiment during the reporting period. Investors will watch how Definium progresses with its clinical trials and market performance in the coming months.
Get Definium Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $DFTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.